Ipilimumab N01 Placebo
Preclinical
Ipilimumab N01 Placebo is one of 4 therapeutic programs targeting Gastric / Gastroesophageal Junction Adenocarcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Gastric / Gastroesophageal Junction Adenocarcinoma
#DrugCompanyPhaseTrials
1Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 3
Iparomlimab and Tuvonralimab
Qilu Pharmaceutical Co., Ltd.Phase 2
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Ipilimumab N01 Placebo
IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric / Gastroesophageal Junction Adenocarcinoma1 trial
A Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Preclinical·NCT07643623·720 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ipilimumab N01 Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]